Literature DB >> 21378088

Metabolic and cardiovascular outcomes in a group of adult patients with Turner's syndrome under hormonal replacement therapy.

Roberta Giordano1, Daniela Forno, Fabio Lanfranco, Chiara Manieri, Lucia Ghizzoni, Ezio Ghigo.   

Abstract

OBJECTIVE: Turner's syndrome (TS) is a rare genetic disorder caused by complete or partial X chromosome monosomy in a phenotypic female, and it is associated with increased morbidity and mortality for cardiovascular diseases, impaired glucose tolerance, and dyslipidemia. SUBJECTS AND METHODS: In 30 adult TS patients under chronic hormonal replacement therapy (HRT), 17β-estradiol (E(2)), body mass index (BMI), waist circumference, fasting glucose and insulin, homeostatic model assessment (HOMA) index, serum lipids, oral glucose tolerance test (OGTT), 24 h ambulatory blood pressure monitoring (ABPM), and intima-media thickness (IMT) were evaluated and compared with those in 30 age- and sex-matched controls (CS).
RESULTS: No difference was found between TS and CS in E(2) and BMI, whereas waist circumference was higher (P<0.05) in TS (77.7±2.5 cm) than in CS (69.8±1.0 cm). Fasting glucose in TS and in CS was similar, whereas fasting insulin, HOMA index, and 2 h glucose after OGTT were higher (P<0.0005) in TS (13.2±0.8 mUI/l, 2.5±0.2, and 108.9±5.5 mg/dl respectively) than in CS (9.1±0.5 mUI/l, 1.8±0.1, and 94.5 ± 3.8 mg/dl respectively). Total cholesterol was higher (P<0.05) in TS (199.4 ± 6.6 mg/dl) than in CS (173.9±4.6 mg/dl), whereas no significant differences in high-density lipoprotein, low-density lipoprotein, and triglycerides were found between the two groups. In 13% of TS, ABPM showed arterial hypertension, whereas IMT was <0.9 mm in all TS and CS. A negative correlation between insulin levels, HOMA index, or 2 h glucose after OGTT and E(2) was present in TS.
CONCLUSIONS: Our results indicate that adult patients with TS under HRT are connoted by higher frequency of central obesity, insulin resistance, hypercholesterolemia, and hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378088     DOI: 10.1530/EJE-11-0002

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

Review 1.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

2.  Amniotic fluid RNA gene expression profiling provides insights into the phenotype of Turner syndrome.

Authors:  Lauren J Massingham; Kirby L Johnson; Thomas M Scholl; Donna K Slonim; Heather C Wick; Diana W Bianchi
Journal:  Hum Genet       Date:  2014-05-22       Impact factor: 4.132

3.  Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with Turner syndrome.

Authors:  Martha Taboada; Richard Santen; John Lima; Jobayer Hossain; Ravinder Singh; Karen Oerter Klein; Nelly Mauras
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

4.  Systematic review of quality of life in Turner syndrome.

Authors:  Carolina Trombeta Reis; Maíra Seabra de Assumpção; Gil Guerra-Junior; Sofia Helena Valente de Lemos-Marini
Journal:  Qual Life Res       Date:  2018-02-09       Impact factor: 4.147

5.  Insulin resistance in adolescents with Turner syndrome is comparable to obese peers, but the overall metabolic risk is lower due to unknown mechanism.

Authors:  M Wojcik; D Janus; A Zygmunt-Gorska; J B Starzyk
Journal:  J Endocrinol Invest       Date:  2014-10-11       Impact factor: 4.256

6.  Prepubertal ultra-low-dose estrogen therapy is associated with healthier lipid profile than conventional estrogen replacement for pubertal induction in adolescent girls with Turner syndrome: preliminary results.

Authors:  Anna Ruszala; Malgorzata Wojcik; Agata Zygmunt-Gorska; Dominika Janus; Joanna Wojtys; Jerzy B Starzyk
Journal:  J Endocrinol Invest       Date:  2017-04-10       Impact factor: 4.256

7.  Levonorgestrel correlates with less weight gain than other progestins during hormonal replacement therapy in Turner Syndrome patients.

Authors:  Andréia Latanza Gomes Mathez; Patrícia Teófilo Monteagudo; Ieda Therezinha do Nascimento Verreschi; Magnus Régios Dias-da-Silva
Journal:  Sci Rep       Date:  2020-05-19       Impact factor: 4.379

Review 8.  Cardiometabolic and vascular risks in young and adolescent girls with Turner syndrome.

Authors:  Meenal Mavinkurve; Clodagh S O'Gorman
Journal:  BBA Clin       Date:  2015-04-30

9.  Aortic elasticity deterioration proves intrinsic abnormality of the ascending aorta in pediatric Turner syndrome unrelated to the aortic valve morphology.

Authors:  Christiane Pees; Julian A Heno; Gabriele Häusler; Diana-Alexandra Ertl; Talin Gulesserian; Ina Michel-Behnke
Journal:  Heart Vessels       Date:  2018-05-18       Impact factor: 2.037

Review 10.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.